Compare IMRX & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMRX | JFIN |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.8M | 330.9M |
| IPO Year | 2021 | 2018 |
| Metric | IMRX | JFIN |
|---|---|---|
| Price | $5.32 | $6.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 687.8K | 55.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.82% |
| EPS Growth | ★ 37.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.35 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.10 | $5.73 |
| 52 Week High | $10.08 | $18.70 |
| Indicator | IMRX | JFIN |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 44.20 |
| Support Level | $3.93 | $5.81 |
| Resistance Level | $5.36 | $6.70 |
| Average True Range (ATR) | 0.28 | 0.30 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 84.82 | 44.39 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.